HYPERION DEFI, INC.
Close on Oct 19, 2026
- Market cap
- $48.74M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $244.27K | $0.26 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | $496.23K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $302.51K | $0.05 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 19, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $1.63K | $-0.11 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted Gross Profitnon-GAAP | 2026 | $5.00M to $7.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Hyperion Defi filed with the SEC
Hyperion DeFi Commences Share Buybacks, Retires
Agreement terminated · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hyperion DeFi Reports 2Q 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperion DeFi © 2026 1 HYPD Q2 2026 Earnings Supplement NASDAQ: HYPD More than just HYPE.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperion DeFi Reports 1Q 2026 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hyperion DeFi © 2026 1
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Hyperion DeFi Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Hyperion DeFi Announces Pricing of Public Offering of Common Stock
Other events · EX-99.2 to Form 8-K
DeFi Reports 4Q and FY 2025 Financial Results with
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperion DeFi © 2026 1 HYPD Q4 2025 and FY 2025 Earnings Supplement More than just HYPE. NASDAQ: HYPD
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperion DeFi Appoints Hyunsu Jung as Chief
Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperion DeFi © 2025 1 HYPD Q3 2025 Earnings Supplement More than just HYPE. NASDAQ: HYPD
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Hyperion DeFi Announces Strategic Partnership
Material agreement · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Hyperion DeFi Announces Appointment of David
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Hyperion DeFi Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Eyenovia Announces Rebranding and Corporate
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Announces Co-Branded Validator with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Eyenovia Announces $50 Million Investment to Launch
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Eyenovia Provides Updates on Potential Merger
Results of operations · EX-99.1 to Form 8-K
Eyenovia Enters into Non-Binding Letter of Intent
Results of operations · Other events · EX-99.1 to Form 8-K
Eyenovia Announces 1-for-80 Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Pricing of $1.3 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Provides Update on Phase 3 CHAPERONE
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Eyenovia Reports Third Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Pricing of $4 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Announces Appointment of Experienced
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Our Vision is to Improve Yours
Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia, Inc. Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Announces Pricing of $5.14 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Eyenovia Reports Second Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
June 2024 We Are the Optejet® Company Developing and commercializing ophthalmic therapeutics with Optecare Ρ services in large markets with high unmet needs EYEN - COM - V2 - 0021
Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial
Results of operations · EX-99.1 to Form 8-K
We Are the Optejet® Company
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Re-Acquires Development and Commercialization
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Eyenovia Reports Third Quarter 2023 Financial
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K